- Home
- CURR vs IMRX Comparison
CURR vs IMRX Comparison
Compare CURR & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- IMRX
- Stock Information
- Founded
- CURR 2013
- IMRX 2008
- Country
- CURR Singapore
- IMRX United States
- Employees
- CURR N/A
- IMRX N/A
- Industry
- CURR Business Services
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- IMRX Health Care
- Exchange
- CURR Nasdaq
- IMRX Nasdaq
- Market Cap
- CURR 74.0M
- IMRX 68.4M
- IPO Year
- CURR N/A
- IMRX 2021
- Fundamental
- Price
- CURR $0.43
- IMRX $2.60
- Analyst Decision
- CURR Strong Buy
- IMRX Strong Buy
- Analyst Count
- CURR 1
- IMRX 4
- Target Price
- CURR $3.50
- IMRX $13.25
- AVG Volume (30 Days)
- CURR 2.5M
- IMRX 2.4M
- Earning Date
- CURR 08-11-2025
- IMRX 08-05-2025
- Dividend Yield
- CURR N/A
- IMRX N/A
- EPS Growth
- CURR N/A
- IMRX N/A
- EPS
- CURR N/A
- IMRX N/A
- Revenue
- CURR $43,386,858.00
- IMRX N/A
- Revenue This Year
- CURR N/A
- IMRX N/A
- Revenue Next Year
- CURR $21.53
- IMRX N/A
- P/E Ratio
- CURR N/A
- IMRX N/A
- Revenue Growth
- CURR N/A
- IMRX N/A
- 52 Week Low
- CURR $0.33
- IMRX $1.00
- 52 Week High
- CURR $7.08
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- IMRX 70.10
- Support Level
- CURR N/A
- IMRX $1.66
- Resistance Level
- CURR N/A
- IMRX $2.24
- Average True Range (ATR)
- CURR 0.00
- IMRX 0.32
- MACD
- CURR 0.00
- IMRX 0.07
- Stochastic Oscillator
- CURR 0.00
- IMRX 89.51
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.